Neuland Laboratories Limited Stock

Equities

NEULANDLAB

INE794A01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:47 2024-05-10 am EDT 5-day change 1st Jan Change
7,134 INR -0.14% Intraday chart for Neuland Laboratories Limited -5.39% +34.93%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 15.59B 187M Sales 2025 * 16.39B 196M Capitalization 91.53B 1.1B
Net income 2024 3B 35.93M Net income 2025 * 3.19B 38.17M EV / Sales 2024 5.17 x
Net cash position 2024 * 2.32B 27.84M Net cash position 2025 * 4.33B 51.85M EV / Sales 2025 * 5.32 x
P/E ratio 2024
26.9 x
P/E ratio 2025 *
28.9 x
Employees 1,554
Yield 2024 *
0.17%
Yield 2025 *
0.14%
Free-Float 61.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.14%
1 week-5.39%
Current month-6.14%
1 month+7.11%
3 months+10.75%
6 months+33.43%
Current year+34.93%
More quotes
1 week
7 019.00
Extreme 7019
7 694.95
1 month
6 620.40
Extreme 6620.4
7 794.00
Current year
5 029.80
Extreme 5029.8
7 794.00
1 year
2 569.45
Extreme 2569.45
7 794.00
3 years
965.85
Extreme 965.85
7 794.00
5 years
247.30
Extreme 247.3
7 794.00
10 years
247.30
Extreme 247.3
7 794.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 01-12-31
Director of Finance/CFO - 22-11-22
Chief Tech/Sci/R&D Officer - Nov. 21
Members of the board TitleAgeSince
Director/Board Member 78 22-10-30
Director/Board Member 80 19-02-11
Director/Board Member 60 23-06-26
More insiders
Date Price Change Volume
24-05-10 7,134 -0.14% 972
24-05-09 7,144 -4.07% 1,069
24-05-08 7,447 +1.24% 1,147
24-05-07 7,356 -1.48% 1,003
24-05-06 7,466 -0.99% 1,433

Delayed Quote Bombay S.E., May 10, 2024 at 06:00 am EDT

More quotes
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7,134 INR
Average target price
8,300 INR
Spread / Average Target
+16.34%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NEULANDLAB Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW